10^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems March 13-15, 2017 London, UK

Biography:

Vladimir Torchilin is a university distinguished Professor and Director at Northeastern University, Center for Pharmaceutical Biotechnology and Nano-medicine, Boston. He completed his Graduation and MS in Chemistry at Moscow University. He completed his PhD and DSc in Polymer Chemistry and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. In 1991, he joined MGH/Harvard Medical School as Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. He was the Chair in Department of Pharmaceutical Sciences from 1998-2008. His research interests include “liposomes, lipid-core micelles, biomedical polymers, drug delivery and targeting, pharmaceutical nano carriers and experimental cancer immunology”. He has published more than 350 original papers (which received more than 30,000 citations), more than 150 reviews and book chapters.

Abstract:

Tumor therapy, especially in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA down-regulating the production of proteins, which are involved in cancer cell resistance, such as Pgp or survivin. Even better response could be achieved such as siRNA could be delivered to tumors together with chemotherapeutic agent. This task is complicated by low stability of siRNA in biological surrounding. Thus, the delivery system should simultaneously protect siRNA from degradation. Additionally, these nano preparations can be loaded into their lipidic core with poorly water soluble chemotherapeutic agents, such as paclitaxel or camptothecin. In experiments with cancer cell monolayers, cancer cell 3D spheroids, and in animals with implanted tumors, it was shown that such co-loaded preparations can significantly down-regulate target proteins in cancer cells, enhance drug activity, and reverse multidrug resistance. In order to specifically unload such nano preparations inside tumors, we made them sensitive to local tumor-specific stimuli, such as lowered pH, hypoxia, or overexpressed certain enzymes, such as matrix metalloproteases. Using pH-, hypoxia-, or MMP2-sensitive bonds between different components of nano preparations co-loaded with siRNA and drugs, we were able to make the systems specifically delivering biologically active agents in tumors, which resulted in significantly improved therapeutic response.

Biography:

Vladimir Torchilin is a university distinguished Professor and Director at Northeastern University, Center for Pharmaceutical Biotechnology and Nano-medicine, Boston. He completed his Graduation and MS in Chemistry at Moscow University. He completed his PhD and DSc in Polymer Chemistry and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. In 1991, he joined MGH/Harvard Medical School as Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. He was the Chair in Department of Pharmaceutical Sciences from 1998-2008. His research interests include “liposomes, lipid-core micelles, biomedical polymers, drug delivery and targeting, pharmaceutical nano carriers and experimental cancer immunology”. He has published more than 350 original papers (which received more than 30,000 citations), more than 150 reviews and book chapters.

<span style="font-size: 12pt; font-family: " times="" new="" roman",="" serif;vladimir="" torchilin="" is="" a="" university="" distinguished="" professor="" and="" director="" at="" northeastern="" university,="" center="" for="" pharmaceutical="" biotechnology="" nano-medicine,="" boston.="" he="" completed="" his="" graduation="" ms="" in="" chemistry="" moscow="" university.="" phd="" dsc="" polymer="" of="" physiologically="" active="" compounds="" 1971="" 1980,="" respectively.="" 1991,="" joined="" mgh="" harvard="" medical="" school="" as="" head="" program,="" imaging="" research,="" associate="" radiology.="" was="" the="" chair="" department="" sciences="" from="" 1998-2008.="" research="" interests="" include="" “liposomes,="" lipid-core="" micelles,="" biomedical="" polymers,="" drug="" delivery="" targeting,="" nano="" carriers="" experimental="" cancer="" immunology”.="" has="" published="" more="" than="" 350="" original="" papers="" (which="" received="" 30,000="" citations),="" 150="" reviews="" book="" chapters.

Abstract:

Tumor therapy, especially in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA down-regulating the production of proteins, which are involved in cancer cell resistance, such as Pgp or survivin. Even better response could be achieved such as siRNA could be delivered to tumors together with chemotherapeutic agent. This task is complicated by low stability of siRNA in biological surrounding. Thus, the delivery system should simultaneously protect siRNA from degradation. Additionally, these nano preparations can be loaded into their lipidic core with poorly water soluble chemotherapeutic agents, such as paclitaxel or camptothecin. In experiments with cancer cell monolayers, cancer cell 3D spheroids, and in animals with implanted tumors, it was shown that such co-loaded preparations can significantly down-regulate target proteins in cancer cells, enhance drug activity, and reverse multidrug resistance. In order to specifically unload such nano preparations inside tumors, we made them sensitive to local tumor-specific stimuli, such as lowered pH, hypoxia, or overexpressed certain enzymes, such as matrix metalloproteases. Using pH-, hypoxia-, or MMP2-sensitive bonds between different components of nano preparations co-loaded with siRNA and drugs, we were able to make the systems specifically delivering biologically active agents in tumors, which resulted in significantly improved therapeutic response.

<span style="font-size: 12pt; font-family: " times="" new="" roman",="" serif;="" tumor="" therapy,="" especially="" in="" the="" case="" of="" multidrug="" resistant="" cancers,="" could="" be="" significantly="" enhanced="" by="" using="" sirna="" down-regulating="" production="" proteins,="" which="" are="" involved="" cancer="" cell="" resistance,="" such="" as="" pgp="" or="" survivin.="" even="" better="" response="" achieved="" delivered="" to="" tumors="" together="" with="" chemotherapeutic="" agent.="" this="" task="" is="" complicated="" low="" stability="" biological="" surrounding.="" thus,="" delivery="" system="" should="" simultaneously="" protect="" from="" degradation.="" additionally,="" these="" nano="" preparations="" can="" loaded="" into="" their="" lipidic="" core="" poorly="" water="" soluble="" agents,="" paclitaxel="" camptothecin.="" experiments="" monolayers,="" 3d="" spheroids,="" and="" animals="" implanted="" tumors,="" it="" was="" shown="" that="" co-loaded="" down-regulate="" target="" proteins="" cells,="" enhance="" drug="" activity,="" reverse="" resistance.="" order="" specifically="" unload="" inside="" we="" made="" them="" sensitive="" local="" tumor-specific="" stimuli,="" lowered="" ph,="" hypoxia,="" overexpressed="" certain="" enzymes,="" matrix="" metalloproteases.="" ph-,="" hypoxia-,="" mmp2-sensitive="" bonds="" between="" different="" components="" drugs,="" were="" able="" make="" systems="" delivering="" biologically="" active="" agents="" resulted="" improved="" therapeutic="" response.

Biography:

Andreas Bernkop-Schnürch was educated in pharmacy (M.Sc.) and in microbiology and genetics (D.Sc.), University of Vienna, finishing his doctorate in 1994. In 2003 he was appointed to a chair in pharmaceutical technology at the University of Innsbruck. Since 2013 he heads the Institute of Pharmacy there. He invented and pioneered thiolated polymers – thiomers – as a new generation of mucoadhesive polymers. Various medicines based on thiomers have already passed clinical trials and a first product will soon reach the global pharmaceutical market. He is the founder of several biotech companies and author of over 300 research articles and reviews. As of June 2016 his H-index is 61.

Abstract:

Within of the last decade biologics became the new, pioneering generation of therapeutics in treatment of numerous diseases. Their fast majority, however, is working through the parenteral route being less accepted and inconvenient, as the oral route for administration of biologics emerged to be problematic mostly due to the enzymatic barrier (I), the mucus gel barrier (II) and the absorption barrier (III) of the GI-tract. To overcome these barriers, a huge variety of strategies were established. Among these different strategies, lipophilic emulsifying delivery systems - having already been established more than 30 years ago for the oral administration of the peptide drug cyclosporine - are nowadays attracting more and more academic and industrial research groups, as the number of encouraging in vivo data and late stage clinical trials is strongly increasing. Among lipophilic emulsifying delivery systems in particular self-emulsifying drug delivery systems (SEDDS) are in focus of research and development. Despite their hydrophilic character biologics can be incorporated in the lipophilic phase of SEDDS via complexation with lipophilic excipients. Once emulsified in the GI-tract to lipid droplets in the size of 30-200 nm, SEDDS provide a protective effect towards a presystemic metabolism without taking the risk of any side effects. Furthermore, SEDDS exhibit comparatively high mucus permeating properties and can be taken up by epithelial cells in an efficient manner. Moreover, SEDDS can be produced very simply and cost effectively.  Because of these properties they seem to be a promising tool for oral administration of biologics.

Biography:

Steve Hood completed his PhD in Molecular Toxicology at Surrey University and joined Glaxo Group Research as a Post-Doctoral Fellow in 1993. Following the formation of GlaxoSmithKline (GSK) in 2001, he managed a team determining the drug-drug interaction liabilities while developing ADME strategies for the emerging GSK antibody portfolio. In 2010, he led a cross divisional team charged with understanding and overcoming the delivery issues inherent in GSK’s diverse oligonucleotide portfolio while helping to develop these molecules from early discovery to file. In 2011, he initiated a project that has grown into the active IMI academic/industry COMPACT collaboration (http://www.compact-research.org/) and he is actively involved in facilitating the interaction between academia, biotech and large industry partners.

Abstract:

Biography:

Prof. (emeritus) Goldblum is Head of the Molecular Modeling and Drug Design and Discovery Unit at the Institute for Drug Research of the Hebrew University. Following a BSc in Chemistry and Physics and a MSc in QM studies of molecular spectra, Goldblum's PhD is in Organic Reaction Mechanisms (Hebrew University) followed by Postdoc studies of Quantum Biochemistry (Paris), and of QSAR and QM reaction mechanisms (California). Back at Hebrew U, Goldblum performed research of protein reactions and interactions using semiempirical QM and developed MNDO/H for dealing with H-bonding in relatively large molecular systems. Since 2000, Goldblum's group focuses on applications of his prize winning generic algorithm (ACS "emerging technologies", Washington D.C. 2000) for finding sets of best solutions in extremely complex combinatorial problems. ISE (Iterative Stochastic Elimination) has been applied to protein structure and conformations, to protein-protein and protein-ligand interactions, to molecular properties and to the discovery of drug candidates.

Abstract:

Remote drug loading into nano-liposomes is in most cases the best method for achieving high concentrations of active pharmaceutical ingredients (API) per nano-liposome that enable therapeutically viable API-loaded nano-liposomes, referred to as nano-drugs.  This approach also enables controlled drug release. Recently, we constructed computational models to identify APIs that can achieve the desired high concentrations in nano-liposomes by remote loading. We model and predict API suitability for nano-liposomal delivery by  fixing the main experimental conditions: liposome lipid composition and size to be similar to those of Doxil® liposomes. On that basis, we add  a prediction of drug leakage from the nano-liposomes during storage. The latter is critical for having pharmaceutically viable nano-drugs. The "load and leak" models were used to screen two large molecular databases in search of candidate APIs for delivery by nano-liposomes. The distribution of positive instances in both loading and leakage models was similar in the two databases screened. The screening process identified 667 molecules that were positives by both loading and leakage models (i.e., both high-loading and stable).  Among them, 318 molecules received a high score in both properties and of these, 67 are FDA-approved drugs. This group of molecules, having diverse pharmacological activities, may be the basis for future liposomal drug development.  .